Trinité, Benjamin
Tarrés-Freixas, Ferran
Rodon, Jordi
Pradenas, Edwards
Urrea, Víctor
Marfil, Silvia
Rodríguez de la Concepción, María Luisa
Ávila-Nieto, Carlos
Aguilar-Gurrieri, Carmen
Barajas, Ana
Ortiz, Raquel
Paredes, Roger
Mateu, Lourdes
Valencia, Alfonso
Guallar, Víctor
Ruiz, Lidia
Grau, Eulàlia
Massanella, Marta
Puig, Jordi
Chamorro, Anna
Izquierdo-Useros, Nuria
Segalés, Joaquim
Clotet, Bonaventura
Carrillo, Jorge
Vergara-Alert, Júlia
Blanco, Julià
Funding for this research was provided by:
ANID (72180406)
GRIFOLS
#joemcorono
Departament de Salut, Generalitat de Catalunya (DSL0016, DSL0016)
Instituto de Salud Carlos III (PI17/01518)
Article History
Received: 24 July 2020
Accepted: 8 January 2021
First Online: 28 January 2021
Competing interests
: Outside the submitted work JB and JC are founders and shareholders of AlbaJuna Therapeutics, S.L. BC is founder and shareholder of AlbaJuna Therapeutics, S.L and AELIX Therapeutics, S.L. The other authors declare no competing interests.